155 related articles for article (PubMed ID: 28293043)
21. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
22. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
23. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
[TBL] [Abstract][Full Text] [Related]
24. Combined Lung-Liver and Delayed Kidney Transplantation for Cystic Fibrosis Clinical Approach and Outcome: A Case Report.
Zhang T; Price MB; Bravo N; Villarreal JA; Kueht ML; Vierling JM; Cotton R; Galvan T; O'Mahony CA; Goss JA; Rana A
Transplant Proc; 2020 Nov; 52(9):2824-2826. PubMed ID: 32389488
[TBL] [Abstract][Full Text] [Related]
25. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.
Patrick A; Wee A; Hedderman A; Wilson D; Weiss J; Govani M
J Neurooncol; 2011 Jul; 103(3):739-43. PubMed ID: 20872273
[TBL] [Abstract][Full Text] [Related]
26. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
27. Rituximab as induction therapy in pediatric kidney transplantation: A single-center experience in four patients.
Bernard J; Sellier-Leclerc AL; Demède D; Chamouard V; Ranchin B; Bacchetta J
Pediatr Transplant; 2022 Sep; 26(6):e14329. PubMed ID: 35655369
[TBL] [Abstract][Full Text] [Related]
28. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
29. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
Bitzan M; Ouahed JD; Carpineta L; Bernard C; Bell LE
Pediatr Nephrol; 2010 Jun; 25(6):1163-7. PubMed ID: 20140460
[TBL] [Abstract][Full Text] [Related]
30. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
Ganzemueller J; Hartmann B; Keller F; Stracke S
Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
32. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
33. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.
Nakanishi C; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Miyagi S; Takeda I; Fukushima D; Kobayashi Y; Ishida K; Niizuma H; Tsuchiya S; Wada M; Nio M; Satomi S
Surg Today; 2012 Aug; 42(8):741-51. PubMed ID: 22278621
[TBL] [Abstract][Full Text] [Related]
34. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
[TBL] [Abstract][Full Text] [Related]
36. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
37. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab.
Alexandru S; Gonzalez E; Grande C; Hernandez A; Morales E; Praga M; Andres A; Morales JM
Transplant Proc; 2009; 41(6):2435-7. PubMed ID: 19715944
[TBL] [Abstract][Full Text] [Related]
38. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report.
Keribin P; Guerrot D; Jardin F; Moizan H
J Oral Maxillofac Surg; 2017 Dec; 75(12):2599-2605. PubMed ID: 28623682
[TBL] [Abstract][Full Text] [Related]
40. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]